M
7.19
0.10 (1.41%)
| Previous Close | 7.09 |
| Open | 7.06 |
| Volume | 94,209 |
| Avg. Volume (3M) | 584,173 |
| Market Cap | 566,966,720 |
| Price / Earnings (Forward) | 47.17 |
| Price / Sales | 14.88 |
| Price / Book | 8.24 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -147.22% |
| Diluted EPS (TTM) | -2.12 |
| Quarterly Revenue Growth (YOY) | 948.50% |
| Total Debt/Equity (MRQ) | 125.02% |
| Current Ratio (MRQ) | 2.03 |
| Operating Cash Flow (TTM) | -104.50 M |
| Levered Free Cash Flow (TTM) | -72.72 M |
| Return on Assets (TTM) | -34.41% |
| Return on Equity (TTM) | -143.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | MeiraGTx Holdings plc | Bullish | Bullish |
AIStockmoo Score
0.4
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 24.66% |
| % Held by Institutions | 58.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sanofi | 31 Dec 2024 | 12,197,737 |
| Johnson & Johnson | 31 Dec 2024 | 6,641,064 |
| 683 Capital Management, Llc | 31 Dec 2024 | 2,415,000 |
| Knoll Capital Management, Llc | 31 Dec 2024 | 1,250,000 |
| J. Goldman & Co Lp | 31 Dec 2024 | 550,520 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 36.00 (Chardan Capital, 400.70%) | Buy |
| Median | 24.50 (240.75%) | |
| Low | 13.00 (RBC Capital, 80.81%) | Buy |
| Average | 24.50 (240.75%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.52 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 17 Mar 2025 | 13.00 (80.81%) | Buy | 7.87 |
| Chardan Capital | 24 Feb 2025 | 36.00 (400.70%) | Buy | 7.17 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Feb 2025 | Announcement | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |